Paul Rivard - Net Worth and Insider Trading
Paul Rivard Net Worth
The estimated net worth of Paul Rivard is at least $26,666 dollars as of 2024-05-28. Paul Rivard is the Chief Legal Officer of MyMD Pharmaceuticals Inc and owns about 13,333 shares of MyMD Pharmaceuticals Inc (MYMD) stock worth over $26,666. Details can be seen in Paul Rivard's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Paul Rivard has not made any transactions after 2023-08-24 and currently still holds the listed stock(s).
Transaction Summary of Paul Rivard
Paul Rivard Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Paul Rivard owns 1 companies in total, including MyMD Pharmaceuticals Inc (MYMD) .
Click here to see the complete history of Paul Rivard’s form 4 insider trades.
Insider Ownership Summary of Paul Rivard
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| MYMD | MyMD Pharmaceuticals Inc | 2023-08-24 | EVP of Operations & GC |
Paul Rivard Latest Holdings Summary
Paul Rivard currently owns a total of 1 stock. Paul Rivard owns 13,333 shares of MyMD Pharmaceuticals Inc (MYMD) as of August 24, 2023, with a value of $26,666.
Latest Holdings of Paul Rivard
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MYMD | MyMD Pharmaceuticals Inc | 2023-08-24 | 13,333 | 2.00 | 26,666 |
Holding Weightings of Paul Rivard
Paul Rivard Form 4 Trading Tracker
According to the SEC Form 4 filings, Paul Rivard has made a total of 4 transactions in MyMD Pharmaceuticals Inc (MYMD) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in MyMD Pharmaceuticals Inc is the acquisition of 5,000 shares on August 24, 2023, which cost Paul Rivard around $166,500.
Insider Trading History of Paul Rivard
- 1
Paul Rivard Trading Performance
GuruFocus tracks the stock performance after each of Paul Rivard's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Paul Rivard is -38.04%. GuruFocus also compares Paul Rivard's trading performance to market benchmark return within the same time period. The performance of stocks bought by Paul Rivard within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Paul Rivard's insider trading performs compared to the benchmark.
Performance of Paul Rivard
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -28.76 | | | | | |
| Relative Return to S&P 500(%) | -28.65 | | | | | |
Paul Rivard Ownership Network
Paul Rivard Owned Company Details
What does MyMD Pharmaceuticals Inc do?
Who are the key executives at MyMD Pharmaceuticals Inc?
Paul Rivard is the EVP of Operations & GC of MyMD Pharmaceuticals Inc. Other key executives at MyMD Pharmaceuticals Inc include director & President & Chief Med. Officer Chapman Christopher C Jr , Chief Scientific Officer Adam Kaplin , and 10 percent owner Caroline C Williams .
MyMD Pharmaceuticals Inc (MYMD) Insider Trades Summary
Over the past 18 months, Paul Rivard made 3 insider transaction in MyMD Pharmaceuticals Inc (MYMD) with a net purchase of 185,000.
In summary, during the past 3 months, insiders sold 0 shares of MyMD Pharmaceuticals Inc (MYMD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of MyMD Pharmaceuticals Inc (MYMD) were sold and 6,167 shares were bought by its insiders, resulting in a net purchase of 6,167 shares.
MyMD Pharmaceuticals Inc (MYMD)'s detailed insider trading history can be found in Insider Trading Tracker table.
MyMD Pharmaceuticals Inc Insider Transactions
Paul Rivard Mailing Address
Above is the net worth, insider trading, and ownership report for Paul Rivard. You might contact Paul Rivard via mailing address: C/o Akers Biosciences, Inc., 1185 Avenue Of The Americas, 3rd Floor, New York Ny 10036.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
